{
  "$schema": "https://json-schema.org/draft/2020-12/schema",
  "type": "object",
  "properties": {
    "references": {
      "type": "array",
      "items": {
        "type": "string"
      },
      "description": "FIRST FIELD - METADATA, NOT VISIBLE TO PATIENT - Array of sources. USE THIS SPACE TO PLAN OUT HOW TO WRITE SIMPLE AND CONCISE DESCRIPTIONS THAT ADHERE TO THE LANGUAGE GUIDELINES."
    },
    "PI": {
      "type": "string",
      "description": "Full name and credentials of principal investigator"
    },
    "Title": {
      "type": "string",
      "description": "Exact title of the study"
    },
    "Study_Site": {
      "type": "string",
      "description": "Full name of site where the study will take place"
    },
    "Cohort": {
      "type": "string",
      "description": "Return \"Affected patient or Recipient\""
    },
    "Contact_Name": {
      "type": "string",
      "description": "Full name of person to contact for questions, without credentials"
    },
    "Contact_Email": {
      "type": "string",
      "description": "Email address of person to contact for questions"
    },
    "Contact_Phone": {
      "type": "string",
      "description": "Phone number of person to contact for questions"
    },
    "Why_Asked": {
      "type": "string",
      "description": "Describe why they are being asked to take part in the research study (simple language)"
    },
    "Study_Purpose": {
      "type": "string",
      "description": "Describe the purpose or objective of the study.  Begin with \"The purpose of this study is to\""
    },
    "Time_Commitment": {
      "type": "string",
      "description": "Expected duration of participation, how many visits, where visits will take place, how long each visit will take, and if there are any overnight stays in the hospital"
    },
    "Brief_Happenings": {
      "type": "string",
      "description": "What will happen during the study including the process for assigning patients to groups and who will know which group patients are assigned to (if applicable). If a group will get a placebo, use the word \"placebo\" then immediately define it as: \"A placebo looks like the study drug but doesn't include any medicine.\""
    },
    "Randomization_Process": {
      "type": "string",
      "description": "REQUIRED LANGUAGE - Describe the randomization process based on study design. (1) If participant will be randomized into exactly two groups, replace [G1] with what group one will get and [G2] with what group two will get: \"If you join this study, you will be assigned by chance (like flipping a coin) to one of two groups. Group 1 will get [G1] and Group 2 will get [G2]. There is an equal chance that you will be assigned to either group. [If study is blinded, include: Neither you nor your doctor will be able to choose or to know which group you are assigned to.]\" (2) If participant will be randomized into one of multiple groups (3 or more), replace [NUMB] with the number of groups, [G1] with what group one will get, [G2] with what group two will get, etc.: \"You will be randomized into one of [NUMB] study groups. Randomization means that you are assigned by chance (like pulling a number from a hat) into one of the groups described below. [If study is blinded, include: Neither you nor your doctor will be able to choose or to know which group you are assigned to.] If you are in Group 1, you will [G1]. If you are in Group 2, you will [G2]. [Continue pattern for all groups]\" If any group receives placebo, use the exact definition: \"A placebo looks like the study drug but doesn't include any medicine.\" (3) If study is not randomized, return empty string."
    },
    "Blinding_Process": {
      "type": "string",
      "description": "Describe the blinding process based on study design. (1) If double-blind: \"You and the study team will not know which study drug you will get. If there is an emergency and it is important for your care, the study team can quickly find out which group you are in.\" (2) If participant-blinded only: \"You will not know which study drug you will get, but your study team will know.\" (3) If investigator-blinded only: \"Your study team will not know which study drug you will get, but you will know.\" (4) If no blinding: return empty string."
    },
    "Abbreviated_Risks": {
      "type": "string",
      "description": "Briefly describe the potential risks and discomforts for the patient if they join this study (comprehensive but brief)"
    },
    "Brief_Alternatives": {
      "type": "string",
      "description": "1-2 sentence summary of alternative treatments, if any, are available to patients even if they do not join the study.  State that they can get alternative treatments, not that they will get alternative treatments"
    },
    "Responsibilities": {
      "type": "string",
      "description": "1-2 sentence summary of what the patient's responsibilities are, like avoiding pregnancy, using effective forms of birth control, stopping breastfeeding, and avoiding certain medications and herbals, foods, and activities (neutral tone)"
    },
    "Brief_Benefits": {
      "type": "string",
      "description": "Brief 1-2 sentence summary of benefits explicitly stated and potential benefits explicitly stated"
    },
    "Voluntariness": {
      "type": "string",
      "description": "Return this statement: \"You are free to stop taking part in the study at any time.  If you want to stop, tell your study doctor.\" Then add 1-2 sentence summary of what (if any) tests or procedures are needed to ensure the patient stops safely"
    },
    "Before_You_Begin": {
      "type": "array",
      "items": {
        "type": "string"
      },
      "description": "Array where each element describes screening activities using procedure library when available. Structure each element as: \"[TIMEPOINT/ACTIVITY]: [PURPOSE FOR ELIGIBILITY]. Activities: [PROCEDURE DESCRIPTIONS USING LIBRARY]. Why this determines eligibility: [SCREENING RATIONALE].\""
    },
    "During_The_Study": {
      "type": "array",
      "items": {
        "type": "string"
      },
      "description": "Array where each element describes study activities using procedure library when available. Structure each element as: \"[TIMEPOINT/EVENT]: [OVERVIEW OF PURPOSE]. Activities: [PROCEDURE DESCRIPTIONS USING LIBRARY]. Why this is important: [RESEARCH RATIONALE].\""
    },
    "Follow_Up": {
      "type": "array",
      "items": {
        "type": "string"
      },
      "description": "Array where each element describes follow-up activities using procedure library when available. Structure each element as: \"[TIMEPOINT/MILESTONE]: [PURPOSE OF THIS FOLLOW-UP]. Activities: [PROCEDURE DESCRIPTIONS USING LIBRARY]. Why we continue monitoring: [LONG-TERM RESEARCH RATIONALE].\""
    },
    "How_Long": {
      "type": "string",
      "description": "Describe the complete time commitment for participants including all study phases"
    },
    "How_Many": {
      "type": "string",
      "description": "Describe the total number of participants who will be enrolled in the study"
    },
    "Risks_Discomforts": {
      "type": "array",
      "items": {
        "type": "string"
      },
      "description": "Array where each element describes one intervention/test/procedure. Follow this order: (1) List all study drugs first, then (2) procedures, then (3) tests. For each procedure: (a) Check procedure_library.json for exact match or synonym, (b) If found in library: use standardized procedure_text and risks_text with study-specific variables filled in, (c) If not found in library: generate following all language guidelines. Structure each array element consistently as: \"[INTERVENTION NAME]: [WHAT IT IS AND PURPOSE]. [HOW IT'S PERFORMED - step by step from patient perspective]. [WHAT PATIENT WILL EXPERIENCE]. Risks include: [COMPREHENSIVE RISK LIST with frequencies/likelihood when known].\" For library procedures, combine procedure_text + \"Risks include: \" + risks_text. For generated procedures, follow same format. Handle special references: if risks_text shows \"REFERENCES: [entry_name]\", include that referenced risk text only once in the final array even if multiple procedures reference it. EXCLUDE pregnancy-related risks and radiation risks from this section as they are captured in separate dedicated fields (Risks_Pregnancy_Title through Fertility_Risk_Men for pregnancy, and Risks_Radiation_Title through RDRC_Reviewed_Rad for radiation)."
    },
    "Risks_Radiation_Title": {
      "type": "string",
      "description": "If there are identified radiation risks, return \"What are the risks of radiation from being in the study?\" If no radiation, return empty string."
    },
    "Rad_Risk_LT3": {
      "type": "string",
      "description": "REQUIRED LANGUAGE - If the Effective Dose (ED) is less than 0.3 rem, return this statement replacing [RAD_PROCS] with the listing of radiological procedures: \"During this research study, you may be exposed to radiation from [RAD_PROCS] each year. This is considered a low exposure. The risk of this exposure is too low to be reliably measured.\" If pediatric participants are included, add: \"The amount of radiation you will get is less than the NIH Radiation Guidelines of 0.5 rem per year for children.\" Then add: \"Every day, people are exposed to low levels of radiation that come from the sun and the environment around them. This type of radiation is called \\\"background radiation.\\\" No one knows for sure whether exposure to these low amounts of radiation is harmful to your body. The radiation you will get by being in this study is less than the average yearly background radiation in the United States.\" If ED ≥ 0.3 rem, return empty string."
    },
    "Rad_Risk_GE3_LT5": {
      "type": "string",
      "description": "REQUIRED LANGUAGE - If the Effective Dose (ED) is ≥ 0.3 rem and < 5.0 rem, return this statement replacing [RAD_PROCS] with radiological procedures, [ED_rem] with the effective dose value, [SCAN_TYPE] with the type of scan, and [YEARS_EQUIVALENT] with years of background (ED ÷ 0.3): \"During this research study, you may be exposed to radiation from [RAD_PROCS] each year. The amount of radiation exposure from these procedures is equal to about [ED_rem]. A rem is a unit of radiation absorbed by the body.\" If pediatric participants, add: \"This amount of radiation is [less than/the same as/greater than] the NIH Radiation Guidelines of 0.5 rem per year for children.\" Then add: \"Every day, people are exposed to low levels of radiation that come from the sun and the environment around them. The average person in the United States receives a radiation exposure of 0.3 rem per year from these sources. This type of radiation is called \\\"background radiation.\\\" No one knows for sure whether exposure to these low amounts of radiation is harmful to your body. The [SCAN_TYPE] that you get in this study will expose you to roughly the same amount of radiation as [YEARS_EQUIVALENT] of background radiation. Most of the time, this amount of extra radiation is not harmful to you. However, scientists believe that being exposed to too much radiation can cause harmful side effects. This could include getting a new cancer. We estimate that this could happen in about 1 out of every 1000 people who get a very large amount of extra radiation.\" If ED < 0.3 or ED ≥ 5.0, return empty string."
    },
    "Rad_Risk_GT5": {
      "type": "string",
      "description": "REQUIRED LANGUAGE - If the Effective Dose (ED) is > 5.0 rem, return this statement replacing [RAD_PROCS], [ED_rem], [SCAN_TYPE], [YEARS_EQUIVALENT] (ED ÷ 0.3), and calculating cancer risk as [ED × 0.1] and fatal cancer risk as [ED × 0.05]: \"During this research study, you may be exposed to radiation from [RAD_PROCS] each year. The amount of radiation exposure from these procedures is equal to about [ED_rem]. A rem is a unit of radiation absorbed by the body. Every day, people are exposed to low levels of radiation that come from the sun and the environment around them. The average person in the United States gets a radiation exposure of 0.3 rem per year from these sources. This type of radiation is called \\\"background radiation.\\\" This study will expose you to more radiation than you get from everyday background radiation. No one knows for sure whether exposure to these low amounts of radiation is harmful to your body. The [SCAN_TYPE] that you get in this study will expose you to roughly the same amount of radiation as [YEARS_EQUIVALENT] of background radiation. Being exposed to too much radiation can cause harmful side effects such as an increase in the risk of cancer. The risk depends on how much radiation you are exposed to. Please be aware that about 40 out of 100 people (40%) will get cancer during their lifetime, and 20 out of 100 (20%) will die from cancer. The risk of getting cancer from the radiation exposure in this study is [ED × 0.1] out of 100 ([ED × 0.1]%) and of getting a fatal cancer is [ED × 0.05] out of 100 ([ED × 0.05]%).\" If ED ≤ 5.0, return empty string."
    },
    "Thera_Rad_Title": {
      "type": "string",
      "description": "If there is therapeutic radiation described in the document, return \"Therapeutic Radiation:\" If no therapeutic radiation, return empty string."
    },
    "Thera_Rad": {
      "type": "string",
      "description": "REQUIRED LANGUAGE - If there is therapeutic radiation, return: \"For assistance drafting risk language specific to a therapy, researchers should contact: • Radioactive therapy drugs (I-131, Lu-177, etc.): the Clinical Authorized User (CAU) signing off on the protocol. A CAU is required for all clinical administrations of radioactive materials. • Radiation Oncology therapies (TBI, SBRT, HDR): Kevin Camphausen or Freddy Escorcia • Additional guidance may be found at https://drs.ors.od.nih.gov/rsc/Pages/forms_index.aspx Risks and side effects related to radiation therapy include: • Likely: [List of risks and side effects] • Less likely: [List of risks and side effects] • Rare, but serious: [List of risks and side effects]\" If no therapeutic radiation, return empty string."
    },
    "Overall_Rad_Risk": {
      "type": "string",
      "description": "If study has BOTH therapeutic radiation AND diagnostic radiation scans, return this statement with appropriate replacements for [TARGET], [THERAPEUTIC_DOSE], [RADIATION_SOURCE], [SCAN_LIST], and optional elements: \"During a year in this research study, [you/your tumor/your target organ] may be exposed to [THERAPEUTIC_DOSE in Gy or rad] of radiation from [RADIATION_SOURCE]. You will also get a much smaller amount of radiation from scans used to plan your treatment and measure your progress. [If applicable: Additionally, tumor biopsies may be done by a specialist using a CT scanner to guide the biopsy needle into the tumor to ensure accuracy.] The total scans include [SCAN_LIST]. The amount of radiation from these scans adds minimal additional risk to the higher radiation doses you would get during treatment. [If applicable: This radiation has been reviewed by the NIH Radiation Safety Committee and deemed appropriate for this study.]\" If study does not have both therapeutic and diagnostic radiation, return empty string."
    },
    "RDRC_Reviewed_Rad": {
      "type": "string",
      "description": "REQUIRED LANGUAGE - If study involves radioactive drugs reviewed by RDRC, return this statement replacing [RAD_PROCS], [ED_rem], [SCAN_TYPE], and [YEARS_EQUIVALENT] (ED ÷ 0.3): \"During your participation in this radioactive drug research study, you may be exposed to radiation from [RAD_PROCS] each year. The amount of radiation exposure from these procedures is equal to about [ED_rem]. A rem is a unit of radiation absorbed by the body. The US Food and Drug Administration (FDA) has set an annual radiation limit of 5 rem for participants for this type of research. The dose you will get in this study is below the limit and is not expected to be harmful. Every day, people are exposed to low levels of radiation that come from the sun and the environment around them. The average person in the United States receives a radiation exposure of 0.3 rem per year from these sources. This type of radiation is called \\\"background radiation.\\\" No one knows for sure whether exposure to these low amounts of radiation is harmful to your body. The [SCAN_TYPE] that you get in this study will expose you to roughly the same amount of radiation as [YEARS_EQUIVALENT] of background radiation. Most of the time, this amount of extra radiation is not harmful to you. However, scientists believe that being exposed to too much radiation can cause harmful side effects. This could include getting a new cancer. We estimate that this could happen in about 1 out of every 1000 people who get a very large amount of extra radiation.\" If not RDRC-reviewed radioactive drug study, return empty string."
    },
    "Risks_Pregnancy_Title": {
      "type": "string",
      "description": "If the study involves pregnancy-related considerations (pregnant participants allowed, OR known/unknown pregnancy risks, OR pregnancy prevention required, OR pregnancy testing conducted), return \"What are the risks related to pregnancy?\" If pregnancy not relevant, return empty string."
    },
    "Risks_Pregnancy_Rationale_Women": {
      "type": "string",
      "description": "Describe the rationale for female pregnancy prevention measures, replacing [STUDY_DRUG] with the study drug or intervention. Return one of four responses: (1) If known human teratogen: \"[STUDY_DRUG] is known to increase the risk of birth defects and miscarriage when taken during pregnancy. There may also be risks for breastfed children. To reduce the risk of harms, women who are pregnant, planning a pregnancy, or breastfeeding cannot be in studies using [STUDY_DRUG].\" (2) If teratogenic in animals but human effects unknown: \"In animal studies, [STUDY_DRUG] increased the risk of some birth defects. We do not know whether these harms could also happen in humans. To reduce the risk of any harms, women who are pregnant, planning a pregnancy, or breastfeeding cannot be in studies with [STUDY_DRUG].\" (3) If risks are unknown: \"The effects of [STUDY_DRUG] on a developing pregnancy or breastfeeding infant are unknown. To reduce the risk of harms, women who are pregnant, planning a pregnancy, or breastfeeding cannot be in studies using [STUDY_DRUG].\" (4) If no safety risks exist: \"Although [STUDY_DRUG] is generally considered safe to use during pregnancy, the changes your body goes through during pregnancy may affect some of the things we are measuring in this study. Therefore, women who are pregnant or planning a pregnancy cannot be in this study.\""
    },
    "Risks_Pregnancy_Rationale_Men": {
      "type": "string",
      "description": "Describe the rationale for male pregnancy prevention measures, replacing [STUDY_DRUG] with the study drug or intervention. Return one of three responses: (1) If known paternal risks exist: \"A higher risk of certain birth defects has been seen in pregnancies where the father was taking [STUDY_DRUG] at the time the pregnancy began. Therefore, men who are trying to become fathers cannot be in studies using [STUDY_DRUG].\" (2) If unknown risk, no seminal transmission: \"We do not know whether pregnancies that began while the father was taking [STUDY_DRUG] are at higher risk for birth defects, miscarriages, or other bad outcomes. To reduce the risk of any harms, men who are trying to become fathers cannot be in studies of this drug.\" (3) If unknown risk + seminal transmission: \"We do not know whether pregnancies that began while the father was taking [STUDY_DRUG] are at higher risk for birth defects, miscarriages, or other bad outcomes. In addition, [STUDY_DRUG] may be present in semen and a partner may be exposed to the study drug during sexual activity. To reduce the risk of any harm, men who are trying to become fathers cannot be in this study.\""
    },
    "Pregnancy_Women_Title": {
      "type": "string",
      "description": "If pregnant patients are allowed or if there are identified or unknown risks to a fetus, return \"For women who can become pregnant:\""
    },
    "Pregnancy_Testing_Requirements": {
      "type": "string",
      "description": "If pregnancy testing is required, return this statement replacing [BLOOD/URINE] with test type: \"If you could possibly become pregnant (you have not completed menopause or haven't had surgery that makes it impossible for you to become pregnant) and if you have a partner who is able to father children, a [BLOOD/URINE] pregnancy test will be done. The pregnancy test must be negative for you to stay in the study.\" If no pregnancy testing required, return empty string."
    },
    "Pregnancy_Testing_Women_Over_Forty": {
      "type": "string",
      "description": "If the study uses serum pregnancy tests AND accepts women over specified age, return this statement replacing [AGE] with the age threshold: \"In women [AGE] and older, blood pregnancy tests may sometimes give a false positive or \\\"indeterminate\\\" (unsure) result. If that happens, we may need to do additional tests to make sure you can still be in the study.\" If study doesn't use serum tests or has different age threshold, return empty string."
    },
    "Required_Contraception_Women": {
      "type": "array",
      "items": {
        "type": "string"
      },
      "description": "REQUIRED ELEMENTS - Return array where first element is the introduction, followed by contraceptive methods, then assistance statement, then effectiveness warning. Structure as: [0] \"You and your partner must agree to one of the following for the entire study, and for [X_TIME] after your last dose of the study drug:\", [1] \"Stop having sex (vaginal intercourse), or\", [2] \"Use a highly effective method of contraception (birth control). These methods include:\", [3] \"Partner vasectomy\", [4] \"Bilateral tubal ligation\", [5] \"Intrauterine devices (IUDs)\", [6] \"Hormonal implants (such as Implanon)\", [7] \"Other hormonal methods (birth control pills, injections, patches, vaginal rings)\", [8] \"If you and your partner are not currently using one of these methods, your study doctor will discuss options with you, given your medical condition, your personal preferences, and the level of effectiveness needed for this study. Because no birth control method is 100% effective, you should tell your study doctor right away if you think there is any chance you could be pregnant, even if you have had a recent negative pregnancy test.\" If ongoing pregnancy testing required, modify final element to emphasize telling doctor even with recent negative test."
    },
    "Pregnancy_Event_Women": {
      "type": "string",
      "description": "Describe actions if pregnancy occurs: \"If you do become pregnant during the study, your study doctor will stop the study drug and notify the sponsor. You will be followed for the entire pregnancy so we can learn about the study drug's potential effects on pregnancy outcomes.\""
    },
    "Fertility_Risk_Women": {
      "type": "string",
      "description": "If there are known or suspected fertility risks for women, return: \"The study drugs used in this study may affect your ability to become pregnant in the future. There may be fertility preservation options available, which your study doctor will discuss with you.\" If no fertility risks, return empty string."
    },
    "Pregnancy_Men_Title": {
      "type": "string",
      "description": "If pregnancy prevention is required for men or if there are risks related to fathering children during the study, return \"For men who can father children:\" If pregnancy prevention not relevant for men, return empty string."
    },
    "Required_Contraception_Men": {
      "type": "array",
      "items": {
        "type": "string"
      },
      "description": "REQUIRED ELEMENTS - Return array for standard contraception scenario (no seminal transmission concern). Structure as: [0] \"If you can father children and your partner could possibly become pregnant (has not completed menopause, or hasn't had surgery that makes it impossible for them to become pregnant), you and your partner must agree to one of the following for the entire study, and for [X_TIME] after your last dose of the study drug:\", [1] \"Stop having sex (vaginal intercourse), or\", [2] \"Use a highly effective method of contraception for the same length of time. Highly effective methods include:\", [3] \"Vasectomy\", [4] \"Bilateral tubal ligation\", [5] \"Intrauterine devices (IUDs)\", [6] \"Hormonal implants (such as Implanon)\", [7] \"Other hormonal methods (birth control pills, injections, patches, vaginal rings)\", [8] \"If you and your partner are not currently using one of these methods, your study doctor will discuss options with you, given your medical condition, your personal preferences, and the level of effectiveness needed for this study. Because no birth control method is 100% effective, you should tell your study doctor immediately if you think there is any chance your partner could be pregnant.\", [9] \"You should not donate sperm for the entire study and for [X_TIME] after your last dose of study drug.\""
    },
    "Seminal_Transmission_Text": {
      "type": "string",
      "description": "REQUIRED ELEMENTS - If study has seminal transmission concerns, return appropriate text. (1) For pregnancy risk only: \"If you are able to father children and your partner could possibly become pregnant (has not completed menopause, or hasn't had surgery that makes it impossible for them to become pregnant), you must agree to either abstain completely from vaginal intercourse for the duration of the study and for [X_TIME] after your last dose of the study drug, or use a condom every time you have vaginal intercourse, even if you have had a vasectomy (because vasectomy does not prevent transmission of the drug in semen). Because no birth control method is 100% effective, you should tell your study doctor immediately if you think there is any chance your partner could be pregnant. If your partner is currently pregnant, breastfeeding, or becomes pregnant during the study, you must use a condom for all types of intercourse to prevent transmission. You should not donate sperm for the duration of the study and for [X_TIME] after your last dose of the study drug.\" (2) For transmission to any partner: \"During sex, your partner could be exposed to the study drug, which could possibly have harmful effects. Therefore, you must agree to use a condom every time you have any type of sex, even if you have had a vasectomy (because the study drug could still be present in your semen). If your partner cannot possibly become pregnant, you must still use a condom to ensure the study drug does not affect your partner or a breastfed baby. You should not donate sperm during the study and for [X_TIME] after your last dose of the study drug.\" If no seminal transmission concerns, return empty string."
    },
    "Pregnancy_Event_Men": {
      "type": "string",
      "description": "Return this exact statement: \"You should notify your partner about being in this study and the potential risks to pregnancies that begin while you are taking the study drug. If your partner does become pregnant during the study, you should tell your study doctor, and your partner should notify their doctor. We will ask for your partner's permission to collect information about the pregnancy so we can learn about the study drug's potential effects on pregnancy outcomes.\""
    },
    "Fertility_Risk_Men": {
      "type": "string",
      "description": "If there are known or suspected fertility risks for men, return: \"The study drug used in this study may affect your ability to father children in the future. There may be fertility preservation options available, which your study doctor will discuss with you.\" If no fertility risks, return empty string."
    },
    "Risks_Study_Drug_Title": {
      "type": "string",
      "description": "If there are study drugs that will be administered, return the appropriate heading. Use \"Risks of Study Drug:\" for single drug studies or \"Risks of Study Drugs:\" for multiple drug studies. If no study drugs are administered, return empty string."
    },
    "Risks_Study_Drug_General": {
      "type": "string",
      "description": "If there are study drugs that will be administered, describe these specific elements: (1) Description of how the study drug may affect different parts of the body (liver, kidneys, lungs, heart, blood, etc.) (2) Description of what the study doctor will do to monitor the different parts of the body that might affect the patient's health"
    },
    "Points_Side_Effects": {
      "type": "array",
      "items": {
        "type": "string"
      },
      "description": "If there is one or more study drug that will be administered, return an array where the first element is the introductory statement, followed by each bullet point as a separate array element. Structure as: [0] \"There is also a risk that you could have side effects from the study drug(s)/study approach. Here are important points about side effects:\", [1-5] Each side effect point as separate element, [6] \"Here are important points about how you and the study doctor can make side effects less of a problem:\", [7-9] Each management point as separate element. Example array: [\"There is also a risk that you could have side effects from the study drug(s)/study approach. Here are important points about side effects:\", \"The study doctors do not know who will or will not have side effects.\", \"Some side effects may go away soon, some may last a long time, or some may never go away.\", \"Some side effects may interfere with your ability to have children.\", \"Some side effects may be serious and may even result in death.\", \"Some side effects may not show up right away and may take days or weeks to appear.\", \"Here are important points about how you and the study doctor can make side effects less of a problem:\", \"Tell the study doctor if you notice or feel anything different so they can see if you are having a side effect.\", \"The study doctor may be able to treat some side effects.\", \"The study doctor may adjust the study drugs to try to reduce side effects.\"]"
    },
    "Potential_Benefits_You": {
      "type": "string",
      "description": "If there are possible benefits identified, return \"You might not benefit from being in this study. However, the potential benefit to you might be\", then describe the potential benefits. If there aren't real or possible benefits return \"You will not benefit from being in this study.\""
    },
    "Potential_Benefits_Others": {
      "type": "string",
      "description": "If others might benefit, return \"In the future, other people might benefit from this study because\" then describe (plainly and simply)"
    },
    "Other_Options": {
      "type": "string",
      "description": "Describe what alternatives to participating in this research study are available, if any, including FDA-approved treatments for the condition being studied"
    },
    "Inclusion_Criteria": {
      "type": "string",
      "description": "1-2 sentence description of the inclusion criteria"
    },
    "Exclusion_Criteria": {
      "type": "string",
      "description": "1-2 sentence description of the exclusion criteria"
    },
    "Parent_Permission": {
      "type": "string",
      "description": "If parental permission is required for a child, return \"If the individual being enrolled is a minor then the term \\\"you\\\" refers to \\\"you and/or your child\\\" throughout the remainder of this document.\""
    },
    "Impaired_Adults": {
      "type": "string",
      "description": "If the study includes adults with impaired decision-making capacity, return \"If the individual being asked to participate in this research study is not able to give consent for themselves, you, as the Legally Authorized Representative, will be their decisionmaker and you are being asked to give permission for this person to be in this study. For the remainder of this document, the term \\\"you\\\" refers to you as the decision-maker and/or the individual being asked to participate in this research.\""
    },
    "Return_Results": {
      "type": "string",
      "description": "Describe the comprehensive plan for returning all results to participants. Address each applicable category: (1) Standard of care results - findings from tests, procedures, and assessments done for regular medical care vs research-only findings, (2) Health-relevant incidental findings - unexpected discoveries from study tests, procedures, or analyses that could affect participant's health, (3) Genetic testing results - including family implications and counseling support, (4) Overall study outcomes - summary findings from the complete study. For each category, specify: what will be shared, timing, method of communication, who will communicate, and what support/referrals will be provided. For studies involving minors, address confidentiality protocols: how sensitive findings from tests or procedures (pregnancy, substance use, mental health) will be handled, when minors will be consulted first, under what circumstances parents/guardians will be informed, and safeguards for minor autonomy. If certain results will not be returned, explain why (research-only, not clinically validated, etc.)."
    },
    "Early_Withdrawal": {
      "type": "string",
      "description": "Describe circumstances under which the investigator may terminate a participant's involvement without the participant's consent. Address: (1) Safety-related withdrawal - situations where continuing poses risk to participant or others, (2) Protocol compliance issues - failure to follow study requirements that could compromise safety or data integrity, (3) Study-wide termination - if the entire study is stopped early, (4) Administrative reasons - loss of funding, regulatory issues, etc. For each applicable scenario, specify: what circumstances trigger withdrawal, how participants will be notified, what happens to their data, and any required follow-up. Include post-withdrawal safety monitoring requirements: what monitoring will continue, for how long, who will provide it, and how it will be conducted. Address whether withdrawn participants can return to regular care and any transition support provided."
    },
    "Disease_Condition": {
      "type": "string",
      "description": "Patient-friendly name of the disease or condition being studied (e.g., stomach cancer). Do not capitalize the first word unless it is a proper noun."
    },
    "Data_Save_Type": {
      "type": "string",
      "description": "Describe data repository access based on the study's data sharing plan. Return the appropriate statement: (1) If the participant's data will be saved in an open access repository: \"The data in the repository will be widely available to anyone who wants it. This means researchers, students, companies, and the general public can access and use your information for their own research or other purposes.\" (2) If the participant's data will be saved in a closed or restricted access repository: \"The data in the repository will only be available to qualified researchers. These researchers must receive permission before they are allowed to access the data. Before receiving the data, the researchers must promise that they will not try to figure out the identity of the research participants.\""
    },
    "Genomic_Sensitivity": {
      "type": "string",
      "description": "Describe genomic summary results sharing based on sensitivity classification. Return the appropriate statement: (1) If the study will create genomic summary results that are NOT deemed sensitive: \"Information about all the people (including you) in this study may be combined to create what is called summary information. The summary information may be placed in a database and shared in scientific publications. This information will help the researchers understand if some patterns are more common than others among everyone who was a part of this study. The summary information will be available to anyone without the need for any permission. The risk of anyone identifying you based on this information is very low.\" (2) If the study will create genomic summary results that ARE deemed sensitive: \"Information about all the people (including you) in this study may be combined to create what is called summary information. The summary information may be placed in a database and will be made available to researchers only if they are granted permission. However, the summary information may still be shared in scientific publications without permissions. This information will help the researchers understand if some patterns are more common than others among everyone who was a part of this study. The risk of anyone identifying you based on this information is very low.\""
    },
    "Anonymized_Specimen_Sharing": {
      "type": "string",
      "description": "If anonymized specimens or data may be used or shared (including in CRIS or BTRIS) then include this statement: \"In addition to the planned use and sharing described above, we might remove any labels from your specimens and data that might identify you (i.e., anonymize them), and use them or share them with other researchers for future studies at the NIH or other places. When we or the other researchers use your anonymized specimens and data for these projects, there will be no way to know that they came from you. We want to make sure that you understand that this is a possibility if you participate in this study. Once we do this, we would not be able to remove your specimens or data from these studies or prevent their use in future studies because we would not be able to tell which specimens or data belong to you.\" However, if anonymized specimens or data will never be shared and data will not be available in CRIS or BTRIS then include this statement: \"We will not remove any labels that might identify you (anonymize) from your specimens and data and use or share them with other researchers for future studies at the NIH or other places.\""
    },
    "Specimen_Storage": {
      "type": "string",
      "description": "Description of the time period specimens will be stored starting with \"Your specimens and data may be stored by the NIH\""
    },
    "Payment_Information": {
      "type": "string",
      "description": "Describe the complete payment structure for study participation. Address all applicable elements based on study design: (1) If no payment: return exact statement \"You will not receive any payment for taking part in this study.\" (2) If payment provided: explain amount, type (check, gift cards, etc.), timing, and minor distribution if applicable. (3) If partial completion possible: include exact statement \"If you are unable to finish the study, you will receive [Partial_Payment] for the parts you completed. If you have unpaid debt to the federal government, please be aware that some or all of your compensation may be automatically reduced to repay that debt on your behalf.\" When replacing [Partial_Payment], this is where itemized payment details by procedure or step must be provided (e.g., \"$50 for each blood draw completed, $100 for each scan completed, $25 for each questionnaire completed\"). This itemized schedule shows participants exactly what they will receive for each specific activity they complete, even if they don't finish the entire study. (4) If payment ≥$600 in calendar year: include exact statement \"With few exceptions, study compensation is considered taxable income that is reportable to the Internal Revenue Service (IRS). A Form 1099-Other Income will be sent to you if your total payments for research participation are $600 or more in a calendar year.\" Combine applicable sections into single comprehensive payment explanation"
    },
    "Reimbursement_Information": {
      "type": "string",
      "description": "Describe the complete reimbursement and travel arrangement policy. Address applicable elements: (1) If no reimbursement provided: return exact statement \"This study does not offer reimbursement for parents and participants, or payment of, hotel, travel, or meals.\" (2) If reimbursement provided: explain what costs will and will not be covered (travel, lodging, meals), whether payments are made as reimbursement to participant or paid directly by NIH, and any requirements or limitations. (3) If NIH arranges and pays for travel: include exact statement \"If your travel to the NIH Clinical Center (e.g., flight, hotel) is arranged and paid for by the NIH, the agency making the reservations and their representatives will have access to your identifiable information.\" Combine applicable sections into single comprehensive reimbursement explanation."
    },
    "Costs": {
      "type": "string",
      "description": "Describe all potential out-of-pocket expenses participants may incur during study participation. Address common cost categories: (1) Transportation costs (gas, parking, public transit, flights not covered by study), (2) Lodging expenses (hotels, extended stays if not reimbursed), (3) Meal costs during study visits, (4) Childcare or eldercare expenses during study activities, (5) Lost wages or time off work, (6) Standard medical care costs (regular doctor visits, medications, tests not part of research), (7) Insurance copays or deductibles for study-related care, (8) Communication costs (long-distance calls, internet for telehealth visits). Include guidance about discussing financial concerns with study team."
    },
    "Conflict_Of_Interest_Information": {
      "type": "string",
      "description": "Describe any conflicts of interest, technology licenses, or Cooperative Research and Development Agreement (CRADA) arrangements. Return the appropriate statement(s): (1) If no technology license and no CRADA: return exact statement \"No NIH investigator involved in this study receives payments or other benefits from any company whose drug, product or device is being tested.\" (2) If technology license exists: include exact statement \"The NIH and the research team for this study have developed [DRUG_DEVICE] being used in this study. This means it is possible that the results of this study could lead to payments to NIH. By law, the government is required to share such payments with the employee inventors. You will not receive any money from the development of [DRUG_DEVICE].\" replacing [DRUG_DEVICE] with actual drug or device name. (3) If Cooperative Research and Development Agreement (CRADA) exists: include exact statement \"NIH and researchers doing this study follow special laws and policies to keep your information as private as possible. However, your identity and information about being in this study may accidentally be seen by others. In most cases, NIH will not share any identifiable information about you unless you say it is okay in writing. More information about sharing your information is below. Information gathered for this study is protected under a Certificate of Confidentiality and the Privacy Act.\" If multiple situations apply, include all relevant statements."
    },
    "Clinical_Trial_Agreement_Information": {
      "type": "string",
      "description": "If there is a clinical trial agreement (CTA), describe the arrangement and investigator payment status. Return the appropriate statement based on investigator composition: (1) If CTA exists and there are NO non-NIH investigators: return exact statement \"[COMPANY_NAME] is providing [DRUG_DEVICE] for this study to NIH without charge. No NIH employee involved in this study receives any payment or other benefits from [COMPANY_NAME].\" replacing [COMPANY_NAME] with company name and [DRUG_DEVICE] with drug/device name. (2) If CTA exists and there ARE non-NIH investigators: return exact statement \"[COMPANY_NAME] is providing [DRUG_DEVICE] for this study to NIH without charge. No NIH investigator involved in this study receives payments or other benefits from any company whose drug, product or device is being tested. However, there are some research partners not associated with the NIH working on this study who may receive payments or benefits, limited by the rules of their workplace.\" replacing [COMPANY_NAME] with company name and [DRUG_DEVICE] with drug/device name. If no CTA exists, return empty string."
    },
    "Confidentiality": {
      "type": "string",
      "description": "Describe confidentiality protections and data handling practices. Address: (1) What identifying information is collected and why (including whether SSN is required), (2) How records are protected (storage methods, access controls, security measures), (3) Who has access to identifiable records (research team, sponsors, regulators, etc.), (4) How long identifiable information is kept, (5) Whether participants can withhold SSN and still participate, (6) Impact of withholding SSN on compensation eligibility if compensation is offered, (7) Any legal requirements for disclosure (court orders, safety reporting, etc.). Structure the response to explain protections first, then address SSN collection and consequences."
    },
    "Confidentiality_Study_Sponsor": {
      "type": "string",
      "description": "If there is a study sponsor, return this exact statement replacing [Study_Sponsor] with the full name of the study sponsor: \"The study Sponsor: [Study_Sponsor]\""
    },
    "Confidentiality_Manufacturer": {
      "type": "string",
      "description": "If there is a manufacturer of a drug or device, return this exact statement replacing [Manufacturer] with the manufacturer name: \"Qualified people from [Manufacturer]\""
    },
    "Confidentiality_Drug_Device": {
      "type": "string",
      "description": "If there are drugs or devices, return this exact statement replacing [Drug_Device] with the names of the drugs or devices: \", and the drug company who makes [Drug_Device]\""
    },
    "FDA_Approval_Status": {
      "type": "string",
      "description": "Describe the FDA approval status of drugs or devices used in the study"
    },
    "Other_Contact_Name": {
      "type": "string",
      "description": "Name of other person, besides the principal investigator, listed as contacts for participants taking part at NIH."
    },
    "Other_Contact_Email": {
      "type": "string",
      "description": "Email of other person, besides the principal investigator, listed as contact for participants taking part at NIH."
    },
    "Other_Contact_Phone": {
      "type": "string",
      "description": "Phone number of other person, besides the principal investigator, listed as contact for participants taking part at NIH."
    },
    "COVID_PREP_Act_Language": {
      "type": "string",
      "description": "REQUIRED LANGUAGE - If study uses a COVID-19 covered countermeasure under the PREP Act Declaration, return this exact statement: \"The NIH Clinical Center will give you short-term medical care for any injury resulting from your participation in research here. In general, no long-term medical care will be given to you by the NIH, the NIH Clinical Center, or the Federal Government.\\n\\nA Declaration under the Public Readiness and Emergency Preparedness (PREP) Act was issued by the Secretary of the United States Department of Health and Human Services on March 10, 2020. This Declaration limits the legal rights of a subject participating in clinical studies using COVID-19 countermeasures. Because this study is covered by the PREP Act Declaration, covered persons, such as the manufacturers, study sponsor, researchers, healthcare providers and others have liability immunity (that is, they cannot be sued by you or your family under the laws of the United States).\\n\\nIf you believe that you may have been harmed because of this research study, certain claims for serious injury or death caused by the countermeasure may be eligible for compensation through the Countermeasures Injury Compensation Program. This is a program set up by the United States Government. Information about this program can be found at https://www.hrsa.gov/cicp/about/index.html or by calling 1-855-266-2427.\" If study does not use COVID-19 covered countermeasures, return empty string."
    }
  },
  "required": [
    "references",
    "PI",
    "Title",
    "Study_Site",
    "Cohort",
    "Contact_Name",
    "Contact_Email",
    "Contact_Phone",
    "Why_Asked",
    "Study_Purpose",
    "Time_Commitment",
    "Brief_Happenings",
    "Randomization_Process",
    "Blinding_Process",
    "Abbreviated_Risks",
    "Brief_Alternatives",
    "Responsibilities",
    "Brief_Benefits",
    "Voluntariness",
    "Before_You_Begin",
    "During_The_Study",
    "Follow_Up",
    "How_Long",
    "How_Many",
    "Risks_Discomforts",
    "Risks_Radiation_Title",
    "Rad_Risk_LT3",
    "Rad_Risk_GE3_LT5",
    "Rad_Risk_GT5",
    "Thera_Rad_Title",
    "Thera_Rad",
    "Overall_Rad_Risk",
    "RDRC_Reviewed_Rad",
    "Risks_Pregnancy_Title",
    "Risks_Pregnancy_Rationale_Women",
    "Risks_Pregnancy_Rationale_Men",
    "Pregnancy_Women_Title",
    "Pregnancy_Testing_Requirements",
    "Pregnancy_Testing_Women_Over_Forty",
    "Required_Contraception_Women",
    "Pregnancy_Event_Women",
    "Fertility_Risk_Women",
    "Pregnancy_Men_Title",
    "Required_Contraception_Men",
    "Seminal_Transmission_Text",
    "Pregnancy_Event_Men",
    "Fertility_Risk_Men",
    "Risks_Study_Drug_Title",
    "Risks_Study_Drug_General",
    "Points_Side_Effects",
    "Potential_Benefits_You",
    "Potential_Benefits_Others",
    "Other_Options",
    "Inclusion_Criteria",
    "Exclusion_Criteria",
    "Parent_Permission",
    "Impaired_Adults",
    "Return_Results",
    "Early_Withdrawal",
    "Disease_Condition",
    "Data_Save_Type",
    "Genomic_Sensitivity",
    "Anonymized_Specimen_Sharing",
    "Specimen_Storage",
    "Payment_Information",
    "Reimbursement_Information",
    "Costs",
    "Conflict_Of_Interest_Information",
    "Clinical_Trial_Agreement_Information",
    "Confidentiality",
    "Confidentiality_Study_Sponsor",
    "Confidentiality_Manufacturer",
    "Confidentiality_Drug_Device",
    "FDA_Approval_Status",
    "Other_Contact_Name",
    "Other_Contact_Email",
    "Other_Contact_Phone",
    "COVID_PREP_Act_Language"
  ]
}